FDA approves Simtriyo for ADHD in ages 6 and older

Federal regulators have approved Simtriyo, a once-daily extended-release tablet containing centanafadine, for the treatment of attention-deficit/hyperactivity disorder (ADHD) in adults and children aged six and older. Officials said the decision clears the drug for prescribing, but final market rollout will still hinge on a separate federal process related to controlled-substance classification.

The company said Simtriyo is the first triple-reuptake inhibitor authorized for ADHD, acting on norepinephrine, dopamine, and serotonin . That mechanism distinguishes it from many existing ADHD therapies that primarily focus on one or two neurotransmitter pathways.

Trial results and the scope of the approval

According to clinical trial results cited with the According to clinical trial results cited with the approval, studies spanning pediatric and adult cohorts enrolled more than 1,000 participants. Across these trials, patients receiving centanafadine showed statistically significant improvements in ADHD symptoms compared with placebo. The indication covers both adults and children starting at age six, aligning it with a large segment of the diagnosed population. However, the available information does not include head-to-head comparisons versus established stimulant or non-stimulant ADHD medications, leaving relative performance questions to be addressed through later evidence. DEA scheduling remains a gating step Despite FDA clearance, Simtriyo remains subject to pending Drug Enforcement Administration (DEA) scheduling hearings that will determine how it is classified. That scheduling outcome can influence prescribing rules, distribution controls, and how quickly clinics and pharmacies integrate a new ADHD drug into routine practice.

Market availability is expected later this year

Market availability is expected later this year , officials said. The timing implies a near-term launch window, but the final start date can shift depending on the scheduling process and operational readiness for distribution.

Safety warnings and early use expectations

The product label includes a boxed warning citing the risk of suicidal ideation in pediatric patients . It also flags the potential for abuse, misuse, and addiction , a key consideration in ADHD care where controlled-substance policies and monitoring practices are common.

Practitioners indicated clinical adoption is expected to be gradual . Early use is anticipated primarily as an alternative for patients who have not achieved adequate benefit with existing stimulant or non-stimulant therapies.

Officials said longer-term market positioning will depend on post-market performance and the emergence of comparative efficacy data versus established treatments. Until such evidence is available, uncertainty remains around where centanafadine will ultimately fit within standard ADHD treatment pathways.

Implications

Country Impact: The decision expands the set of FDA-authorized ADHD treatment options in the United States for both adults and children aged six and older. The practical availability timeline still depends on DEA scheduling hearings, which can affect how the drug is prescribed and dispensed.

Industry Impact: For clinicians and manufacturers, the approval introduces the first triple-reuptake inhibitor authorized for ADHD, potentially widening therapeutic choices for patients who have not responded to current stimulant or non-stimulant options. A boxed warning on suicidal ideation in pediatric patients and risks related to abuse, misuse, and addiction is likely to shape monitoring and prescribing practices.

Market Impact: Market entry is expected later this year, but the rollout is tied to the outcome of DEA scheduling. Longer-term commercial positioning is expected to depend on post-market performance and the availability of comparative data versus established ADHD medications.